PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 11240413

[Statins and stroke].

G V Osseby·E Manceau·M Lemesle-Martin·V Thomas·M Giroud
View original source ↗Export metadata ↓

Abstract

The role of cholesterol in the pathogenesis of stroke, the role of the treatment of hypercholesterolemia in the prevention of stroke have been controversed. The explanation was based on the heterogenous characteristics of stroke, on the relationship between several risk factors, and on the role of the age, in the evaluation of these 2 questions. The discovery of statins induced major therapeutic trials whose aim was the impact on coronary events. These trials demonstrated that statins were accompanied with a major reduction of cholesterol levels and stroke events similar to the one observed with coronary events. Even prospective, placebo controlled, randomized specific trials for stroke are necessary, we can state that cholesterol reduction is the most important mechanism accounting for a decrease in stroke occurrence with statins.

Explore related subjects

Anticholesteremic AgentsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypercholesterolemiaLipidsLovastatinRisk FactorsStrokeEnglish AbstractJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

G V Osseby, E Manceau, M Lemesle-Martin, V Thomas, M Giroud. 2001. [Statins and stroke].. https://pubmed.ncbi.nlm.nih.gov/11240413/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2003

Statin therapy and small fibre neuropathy: a serial electrophysiological study.

We describe three patients who developed small fibre neuropathy after 1 month of statin therapy with clinical resolution upon prompt drug withdrawal. All patients showed abnormal sympathetic skin responses (SSR) in comparison with controls. SSRs returned to normal in tandem with clinical improvement. One patient redeveloped small and large fibre neuropathy when the similar drug was readministered. The SSR is of value in the electrophysiological assessment and follow-up of statin-related small fibre neuropathy.

Anticholesteremic Agents↗
PubMed2003

Cyclodextrins differentially mobilize free and esterified cholesterol from primary human foam cell macrophages.

Human monocyte-derived foam cell macrophages (HMFCs) are resistant to cholesterol efflux mediated by physiological acceptors. The role of the plasma membrane in regulating depletion of free cholesterol (FC) and of cholesteryl ester (CE) was investigated using cyclodextrins (CDs). HMFCs were incubated in media containing CDs (1.0 mg/ml, approximately 0.7 mM) with low [hydroxypropyl-beta-CD (HP-CD)] or high [trimethyl-beta-CD (TM-CD)] affinity for cholesterol in the presence or absence of phospholipid vesicles (PLVs). Low-affinity HP-CD caused minimal cholesterol efflux on its own, but HP-CD+ PLV depleted cell FC and CE to 54.5 +/- 6.7% of control by 24 h. TM-CD depleted FC at least as well as HP-CD+PLV but without depleting CE, even when combined with PLV. This was not explained by acceptor saturation, instability of PLV vesicles, de novo cholesterol synthesis, kinetically distinct cholesterol pools, or inhibition of CE hydrolysis. TM-CD did, however, deplete CE when lower concentrations of TM-CD were combined with PLV and when acetyl-CoA cholesteryl acyltransferase was inhibited. TM-CD caused much greater depletion of plasma membrane cholesterol than HP-CD without depleting plasma membrane sphingomyelin. It is concluded that differential depletion of plasma membrane cholesterol pools regulates cholesterol efflux and CE clearance in human macrophages.

Anticholesteremic Agents↗